Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

The Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research opportunity is administered by the National Institutes of Health through the National Cancer Institute under the Department of Health and Human Services. This funding initiative is part of the Innovative Molecular Analysis Technologies program, which is designed to stimulate technological innovation that advances cancer research capabilities. The program specifically supports projects that have already demonstrated feasibility through preliminary data and are now positioned for further refinement, optimization, and validation to ensure broader adoption by the scientific and clinical research community. The primary objective of this funding opportunity is to accelerate the development of emerging technologies that can significantly enhance the understanding, detection, diagnosis, and treatment of cancer. Eligible projects must focus on technologies that offer new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems. Areas of emphasis include cancer biology, early detection and screening, clinical diagnostics, treatment approaches, cancer control, and epidemiology. Technologies may span a wide range of domains, including molecular and cellular analysis platforms, multi-omic and spatial profiling tools, imaging and sensing systems, immuno-engineering approaches, and innovations in biospecimen processing and modeling. Funding is provided in the form of discretionary grants, with an expected fourteen awards and an estimated total program funding of six million six hundred thousand dollars. Individual awards may reach up to three hundred thousand dollars. The funding is intended to support advanced development activities, including technical optimization and rigorous validation, rather than early-stage exploratory research or simple application of existing technologies to new clinical questions. Projects that do not demonstrate technical novelty or that focus solely on applying established methods without innovation are not considered responsive to this opportunity. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of organizational types. Eligible applicants include nonprofit organizations with and without tax-exempt status, institutions of higher education both public and private, small and large businesses, state and local governments, tribal governments and organizations, special district governments, and certain federal and international entities. Additional eligible applicants include faith-based and community-based organizations, regional organizations, and non-domestic institutions. This broad eligibility framework reflects the program’s goal of fostering innovation across diverse sectors and encouraging collaboration among academic, governmental, and private entities. The application process is expected to follow standard NIH submission procedures, requiring applicants to prepare and submit a full proposal through designated federal grant systems. While specific application components are not detailed in the forecast notice, typical NIH submissions include a detailed research plan, budget justification, biosketches, and supporting documentation demonstrating prior feasibility and technical readiness. Applications are evaluated based on scientific merit, innovation, feasibility, and potential impact on cancer research and clinical practice. The opportunity is currently in a forecasted stage, with an estimated application posting date of January 15, 2027, and an anticipated application deadline of June 4, 2027. Awards are expected to be made by April 1, 2028, with project start dates projected for mid-April 2028. The program does not require cost sharing or matching contributions. Interested applicants may contact the program office via the provided email or phone number for additional information or clarification. This funding opportunity represents a strategic effort by the National Cancer Institute to advance cutting-edge technologies that can transform cancer research and improve clinical outcomes.

Ensure strong preliminary data demonstrating feasibility and focus on technological innovation rather than application of existing methods